<DOC>
	<DOC>NCT00414544</DOC>
	<brief_summary>This is a randomized, double-blind pivotal study to evaluate the safety and effectiveness of CosmetaLife injectable dermal filler for the correction of wrinkles and folds, such as nasolabial folds (i.e., smile lines).</brief_summary>
	<brief_title>Evaluation of the Safety and Efficacy of CosmetaLifeâ„¢ for the Correction of Nasolabial Folds</brief_title>
	<detailed_description>Patients with negative reaction skin test results will be randomized to receive CosmetaLife in one nasolabial fold and Control in the nasolabial fold on the opposite side of the face (split face design). Each subject will serve as his or her own control, allowing for comparison of the outcome between the contralateral sides. Patients will be followed at 2 weeks and 3, 6, 9 and 12 months post treatment for assessment of safety and effectiveness.</detailed_description>
	<criteria>1. Patients 18 years of age or older 2. Patients with moderate nasolabial folds (34 WSRS scale) 3. Patients willing to provide written informed consent for their participation in the study 4. Patients willing to abstain from other facial cosmetic procedures through the 12 month followup visit 1. Patients with any aesthetic facial therapy within 6 months prior to 2. Patients with an any reaction to the skin test 3. Patients with a history of autoimmune disorder, lidocaine reactions, allergy to heparin, other severe or chronic allergies 4. Patients with a current disease state that can effect the immunoresponse, or patients on immunosuppressive therapy 5. Patients with an active infection of any kind, skin disease, connective tissue disorder 6. Patients who are pregnant or lactating 7. Patients enrolled in another investigational clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Nasolabial folds</keyword>
	<keyword>Dermal filler</keyword>
	<keyword>Injectable dermal filler</keyword>
	<keyword>Soft tissue augmentation</keyword>
</DOC>